VELDONA® Pet will hit cabinets in Taiwan in June, with launches in different areas to comply with
Multiple new VELDONA® Pet merchandise set to launch as Ainos enters the rising world pet care market
SAN DIEGO, CA / ACCESSWIRE / May 30, 2023 / Ainos, Inc. (NASDAQ: AIMD, AIMDW) (“Ainos”, or the “Company”), a diversified medtech firm centered on the event of novel point-of-care testing, low-dose interferon therapeutics, and artificial RNA-driven preventative medication, at this time introduced that it has launched its VELDONA® Pet cytoprotein well being dietary supplements. VELDONA® Pet will first be marketed in Taiwan in June, with near-term plans to broaden gross sales and advertising in different markets. Multiple new VELDONA® Pet merchandise are within the works. Ainos targets roughly US$20 million in revenues from VELDONA® Pet throughout 2024, boosted by its rising product portfolio and enlargement into new markets.
Chun-Hsien Tsai, Ainos’ Chairman of the Board, President, and Chief Executive Officer, commented, “The second half of 2023 will probably be a really thrilling interval for Ainos. In addition to Taiwan, we’re actively working to develop larger market alternatives for VELDONA® Pet in Asia and the United States. There is a big addressable marketplace for our product: China has round 117 million pet dogs and cats, Japan has roughly 18 million, and the U.S. has 190 million. We anticipate that VELDONA® Pet merchandise will position us to seize the profitable world pet care market, which is projected to develop to over US$325 billion in 2028 from US$223 billion in 2021, in accordance with Fortune Business Insights.”
“We are growing a number of new merchandise primarily based on VELDONA® Pet to offer pet homeowners with extra revolutionary choices to help their pets’ well being,” Mr. Tsai mentioned. “Boosted by our rising product portfolio and enlargement into new markets, our ambition is that VELDONA® Pet will generate roughly US$20 million in revenues throughout 2024.”
“The introduction of Ainos’ VELDONA® Pet well being dietary supplements in Taiwan marks the start of a brand new chapter in our firm’s story,” Mr. Tsai added. “We leveraged 40 years of interferon analysis to develop VELDONA® Pet, which now serves as a significant part of our subsequent stage of development. The proven fact that we have been in a position to deliver it to market 1 / 4 forward of schedule is yet one more testomony to our group’s unparalleled experience and skill to execute.”
“We anticipate VELDONA® Pet to be available on the market in Taiwan in June. With roughly one in 4 Taiwanese households now proudly owning pets, Taiwan is the perfect location for our product launch. There are at the moment round three million pet dogs and cats in Taiwan, surpassing the variety of kids underneath 14 years old, and this quantity is projected to develop to 4 million by 2025. Recognizing the numerous market alternative, the U.S. Department of Agriculture Foreign Agricultural Service just lately highlighted Taiwan as one of many 4 nations with the ‘best prospects‘ for U.S. pet meals exporters,” Mr. Tsai mentioned.
About VELDONA® Pet
Based on Ainos’ low-dose oral interferon-alpha (“IFNα”) formulation, VELDONA® Pet dietary supplements are backed by quite a few analysis research and scientific trials, and are manufactured with world-class supplies in a extremely licensed food-grade plant. VELDONA® maintains immunity and contributes to gum and pores and skin well being, relieving allergy symptoms and lowering stress in cats and dogs. Interferon is of course produced by an organism’s physique. When cells are invaded by overseas particles, immune signaling molecules notify neighboring cells. Once neighboring cells obtain the interferon’s protein sign by their floor receptors, they provoke and modulate the immune system to guard felines and canines from gum and pores and skin ailments, allergy symptoms, and stress-related situations.
A scientific research, sponsored by Ainos and performed by the state-of-the-art Agricultural Technology Research Institute, has demonstrated that VELDONA® helps preserve the immune techniques of cats and dogs. Numerous research have reported the advantages of interferons in sustaining gum well being and pores and skin well being, relieving discomfort brought on by allergy symptoms, and soothing emotional stress in cats and dogs. VELDONA® Pet not solely supplies safety towards widespread and hard-to-diagnose ailments together with feline persistent gingivostomatitis (FCGS), a extreme oral mucosal inflammatory illness afflicting cats, and canine atopic dermatitis (CAD), an inflammatory pores and skin illness present in dogs, but additionally affords the most secure and highest high quality merchandise in the marketplace.
About Ainos, Inc.
Headquartered in San Diego, California, Ainos, Inc. is a diversified medtech firm engaged in growing revolutionary medical applied sciences for point-of-care testing and secure and novel medical remedy for a broad vary of illness indications. In addition to its proprietary therapeutics utilizing low-dose non-injectable interferon, Ainos has additionally expanded its product portfolio to incorporate Volatile Organic Compounds (VOC) and COVID-19 POCTs. Powered by its AI Nose platform, the lead POCT candidate, Ainos Flora, is a telehealth-friendly POCT for girls’s well being and sure widespread STIs. To be taught extra, go to https://www.ainos.com.
Follow Ainos on Twitter (@AinosInc) and LinkedIn to remain up-to-date.
Forward-Looking Statements
This press launch accommodates “forward-looking statements” about Ainos throughout the that means of the secure harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements might be recognized by way of phrases resembling “anticipate,” “consider,” “estimate,” “anticipate,” “intend,” “plan,” “predict,” “venture,” “goal,” “future,” “probably,” “technique,” “foresee,” “might,” “steerage,” “potential,” “outlook,” “forecast,” “ought to,” “will” or different comparable phrases or phrases. Similarly, statements that describe the Company’s goals, plans or objectives are, or could also be, forward-looking statements. Forward-looking statements are primarily based solely on the Company’s present beliefs, expectations, and assumptions. Forward-looking statements are topic to inherent uncertainties, dangers, and modifications in circumstances which can be troublesome to foretell and lots of of that are exterior of the Company’s management. The Company’s precise outcomes might differ materially from these indicated within the forward-looking statements.
Important components that would trigger the Company’s precise outcomes to vary materially from the projections, forecasts, estimates and expectations mentioned on this press launch embody, amongst others, the cost of manufacturing and gross sales potential of the deliberate drug therapies introduced on this press launch; the Company’s dependence on revenues from the sale of COVID-19 take a look at kits; the Company’s restricted money and historical past of losses; the Company’s capacity to realize profitability; the Company’s capacity to lift further capital to proceed the Company’s product growth; the flexibility to precisely predict the long run working outcomes of the Company; the flexibility to advance Ainos’ present or future product candidates by scientific trials, acquire advertising approval and finally commercialize any product candidates the Company develops; the flexibility to acquire and preserve regulatory approval of Ainos product candidates; delays in finishing the event and commercialization of the Company’s present and future product candidates, which may end in elevated prices to the Company, delay or restrict the flexibility to generate income and adversely have an effect on the business, monetary situation, outcomes of operations and prospects of the Company; intense competitors and quickly advancing know-how within the Company’s trade which will outpace its know-how; buyer demand for the services the Company develops; the impression of aggressive or various merchandise, applied sciences and pricing; disruption in analysis and growth services; lawsuits and different claims by third events or investigations by varied regulatory businesses governing the Company’s operations; potential cybersecurity assaults; elevated necessities and prices associated to cybersecurity; the Company’s capacity to appreciate the advantages of third social gathering licensing agreements; the Company’s capacity to acquire and preserve mental property safety for Ainos product candidates; compliance with relevant legal guidelines, rules and tariffs; and the Company’s success in managing the expansion. A extra full description of those threat components and others is included within the “Risk Factors” part of Ainos’ most recent Annual Report on Form 10-Okay and different experiences filed with the U.S. Securities and Exchange Commission, lots of which dangers are past the Company’s management. In addition to the dangers described above and within the Company’s Form 10-Okay, different unknown or unpredictable components additionally may trigger precise outcomes to vary materially from the projections, forecasts, estimates and expectations mentioned on this press launch.
The forward-looking statements made on this press launch are expressly certified of their entirety by the foregoing cautionary statements. Ainos undertakes no obligation to, and expressly disclaims any such obligation to, publicly update or revise any forward-looking assertion to replicate modified assumptions, the prevalence of anticipated or unanticipated occasions or modifications to the long run outcomes over time or in any other case, besides as required by legislation.
Investor Relations Contact
ICR, LLC
Robin Yang
Tel: +1 646-224-6971
Email: [email protected]
SOURCE: Ainos, Inc.
